These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23471472)

  • 1. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.
    Luo J; Li X; Wu Y; Lin G; Pang Y; Zhang X; Ao Y; Du Z; Zhao Z; Chong Y
    Int J Med Sci; 2013; 10(4):427-33. PubMed ID: 23471472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
    Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis.
    Luo A; Jiang X; Ren H
    Medicine (Baltimore); 2018 Dec; 97(51):e13596. PubMed ID: 30572464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral efficacy of entecavir in nucleos(t)ide-naïve patients of Black/African descent with chronic hepatitis B.
    Jeffers L; Van Rensburg CJ; Banks A; Schechter M; Schmidt SJ; Hu W; Llamoso C; Parana R
    J Viral Hepat; 2014 Jan; 21(1):74-6. PubMed ID: 24112755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.
    Aljumah AA; Bin Selayem NA; Al-Howti SY; Dafallah M; AlGhamdi H; Mokhtar H; Albekairy AM; Sanai FM
    J Infect Chemother; 2019 Jan; 25(1):12-16. PubMed ID: 30366861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load.
    Luo J; You X; Chong Y; Wu Y; Gong J; Jie Y; Li X; Xi S; Zhang Z; Zhang Y; Xie D; Li Z; Li X
    Exp Ther Med; 2019 Jul; 18(1):260-268. PubMed ID: 31258661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
    Geng J; Bao H; Chen Y; Shi L; Geng J; Wang Q; Yu H
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):823-834. PubMed ID: 32329638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.
    Zoutendijk R; Reijnders JG; Brown A; Zoulim F; Mutimer D; Deterding K; Petersen J; Hofmann WP; Buti M; Santantonio T; van Bömmel F; Pradat P; Oo Y; Luetgehetmann M; Berg T; Hansen BE; Wedemeyer H; Janssen HL;
    Hepatology; 2011 Aug; 54(2):443-51. PubMed ID: 21563196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.